New ‘smokeless’ tobacco device has 90% less toxicants

New ‘smokeless’ tobacco cigarettes have been hailed a safer alternative to traditional smoking. 

Now scientists have tested leading product Glo and found it produces 90 percent less toxic substances than cigarettes.

E-cigarettes contain a liquid form of nicotine that is heated into vapour to be inhaled, avoiding the harm caused by tobacco smoke.

But in ‘heat-not-burn’ products such as the Glo, the vapour passes through a bit of tobacco near the tip that imparts flavour in a bid to appeal to cigarette-lovers.

Because the devices heat tobacco as opposed to burning, it does not produce smoke or the toxic substances found in conventional cigarette smoke.

In November 2016, British American Tobacco announced the launch of glo in Japan

Similar to a cigarette, but with reduced risk potential, glo heats rather than burns tobacco

Similar to a cigarette, but with reduced risk potential, glo heats rather than burns tobacco

The tests, carried out by British American Tobacco which manufactuers Glo, found other ‘new generation products’ (NGP)– which include an e-cigarette – had similar lowered levels of toxicants.

‘Although more long-term tests are needed, taken together these results suggest the cigarettes are at the opposite end of a potential risk spectrum to glo and other NGPs like e-cigarettes,’ said Dr James Murphy, head of reduced risk substantiation at British American Tobacco. 

SMOKELESS DEVICES SET TO EXPLODE IN POPULARITY 

Experts predict that heat-not-burn devices are set soar in popularity.

A study published earlier this month suggests they will overtake sales of e-cigarettes, which are used by an estimated 9 million adults in the US and around 2.9 million in the UK.

This has caused campaigners to warn there is an ‘urgent need’ for more research into the health effects of devices which heat tobacco as opposed to burning it.

A team from the US analysed Google search trends relating to the heat-not-burn devices in Japan, which was the first country to sell them.

Their findings showed a huge surge in demand for the items – rising by 2,956 per cent in the two years from 2015 to 2017.

It’s now expected that the same could happen in other countries, after the first heat-not-burn device became available in the UK in November last year and products entered the FDA-approval process in the US in May. 

Study coauthor Mark Dredze, professor of computer science at Johns Hopkins University, said: ‘Heat-not-burn products have quickly become insanely popular.

‘Two years ago, there were essentially no queries in Japan for heat-not-burn tobacco, but now there are between 5.9 and 7.5 million each month.’ 

Campaign group ASH said there is an ‘urgent need’ for independent research into these new devices. 

How the research was carried out

Seven products were assessed, including three cigarettes, glo™ and another tobacco heating product (THP), a hybrid tobacco product and an e-cigarette. 

Scientists programmed robots in a lab to puff on them to produce smoke and vapour in a realistic way.

The smoke and vapour produced was then tested for toxicants known to be present in new generation products and cigarette smoke.

All the NGPs – the glo, e-cigarette, other THP and a hybrid THP showed similar reductions in toxic compounds.

E-cigarette safety debate

The health effects of e-cigarettes has been debated since they entered the US and European market in 2006.

Studies have produced conflicting results, with some linking them to raised risk of bladder cancer, lung disease and heart damage.

According to Public Health England, ‘current best estimate’ is that e-cigarettes are around 95% less harmful than smoking.

Last month, the organization promoted them in TV adverts as part of a campaign urging smokers to switch to them.

However another official body – the drugs rationing watchdog NICE – told GPs not to recommend e-cigarettes because there is limited evidence over whether they are safe.

  • British American Tobacco have invested more than US$1.5 billion over six years in developing a world-leading portfolio of products in the NGPs category.

    The results are published in the Journal Regulatory Toxicology and Pharmacology.

    Read more at DailyMail.co.uk